PMID- 33300072
OWN - NLM
STAT- MEDLINE
DCOM- 20210504
LR  - 20210705
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 23
IP  - 2
DP  - 2021 Feb
TI  - miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 
      in non‑small‑cell lung cancer.
LID - 124 [pii]
LID - 10.3892/mmr.2020.11763 [doi]
AB  - Non‑small‑cell lung cancer (NSCLC) accounts for 80% of lung cancer cases, and is 
      the leading cause of cancer‑associated mortality worldwide. The present study 
      aimed to investigate the roles of microRNA (miR)‑654‑3p in NSCLC. The expression 
      levels of miR‑654‑3p and its target ras protein activator like 2 (RASAL2) mRNA 
      were determined by reverse transcription‑quantitative polymerase chain reaction; 
      protein expression was analyzed by western blotting. Plasmids expressing 
      miR‑654‑3p mimics were constructed and transfected into A549 cells. In addition, 
      the viability and apoptotic rate of cells were analyzed by an MTT assay and flow 
      cytometry, respectively. A luciferase reporter assay was performed to verify 
      whether RASAL2 is a target of miR‑654‑3p. Downregulated miR‑654‑3p and 
      upregulated RASAL2 expression were observed in tumor tissues and cells. Cell 
      viability was suppressed and the apoptotic rate was increased in the miR‑654‑3p 
      mimics‑transfected cells compared with the control. Luciferase activity was 
      decreased in the RASAL2‑3' untranslated region‑wild type group treated with 
      miR‑654‑3p mimics. Furthermore, the present study revealed that overexpression of 
      miR‑654‑3p could suppress the viability and induce the apoptosis of cells by 
      targeting RASAL2 in NSCLC. The present findings may contribute to developments in 
      the treatment of NSCLC.
FAU - Xiong, Jie
AU  - Xiong J
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Xing, Shigang
AU  - Xing S
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Dong, Zheng
AU  - Dong Z
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Niu, Lei
AU  - Niu L
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Xu, Qinghua
AU  - Xu Q
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Li, Yusheng
AU  - Li Y
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Liu, Pingyi
AU  - Liu P
AD  - Department of Clinical Laboratory, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
FAU - Yang, Peixia
AU  - Yang P
AD  - Department of Respiratory Medicine, Linyi Central Hospital, Linyi, Shandong 
      276400, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (GTPase-Activating Proteins)
RN  - 0 (MIRN654 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RASAL2 protein, human)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - A549 Cells
MH  - Aged
MH  - *Apoptosis
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/pathology
MH  - Cell Survival
MH  - Female
MH  - GTPase-Activating Proteins/genetics/*metabolism
MH  - Humans
MH  - Lung Neoplasms/genetics/*metabolism/pathology
MH  - Male
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - RNA, Neoplasm/genetics/*metabolism
PMC - PMC7751472
OTO - NOTNLM
OT  - miR‑654‑3p
OT  - non‑small‑cell lung cancer
OT  - ras protein activator like 2
OT  - proliferation
OT  - apoptosis
EDAT- 2020/12/11 06:00
MHDA- 2021/05/05 06:00
PMCR- 2020/12/08
CRDT- 2020/12/10 05:59
PHST- 2018/03/09 00:00 [received]
PHST- 2018/11/09 00:00 [accepted]
PHST- 2020/12/10 05:59 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/05/05 06:00 [medline]
PHST- 2020/12/08 00:00 [pmc-release]
AID - 124 [pii]
AID - MMR-0-0-11763 [pii]
AID - 10.3892/mmr.2020.11763 [doi]
PST - ppublish
SO  - Mol Med Rep. 2021 Feb;23(2):124. doi: 10.3892/mmr.2020.11763. Epub 2020 Dec 10.